Literature DB >> 8943879

Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia.

H Tamaki, H Ogawa, K Inoue, T Soma, T Yamagami, S Miyake, Y Oka, Y Oji, T Tatekawa, A Tsuboi, S Tagawa, T Kitani, K Aozasa, T Kishimoto, H Sugiyama, H Miwa, K Kita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8943879

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.

Authors:  Caroline Masserot; Qingyuan Liu; Eric Nguyen; Charles-Henry Gattolliat; Dominique Valteau-Couanet; Jean Bénard; Catherine Huber; Evelyne Ségal-Bendirdjian
Journal:  Mol Oncol       Date:  2015-10-21       Impact factor: 6.603

3.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

4.  Different kinetics of WT1 and PML-RARalpha gene expression levels during remission induction therapy with all-trans retinoic acid alone in acute promyelocytic leukemia.

Authors:  Hiroya Tamaki; Tamotsu Yamagami; Manabu Kawakami; Eui Ho Kim; Machiko Mishima; Ichiro Kawase; Toshihiro Soma; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

5.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

6.  An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Authors:  Anna Sergeeva; Gheath Alatrash; Hong He; Kathryn Ruisaard; Sijie Lu; James Wygant; Bradley W McIntyre; Qing Ma; Dan Li; Lisa St John; Karen Clise-Dwyer; Jeffrey J Molldrem
Journal:  Blood       Date:  2011-02-04       Impact factor: 22.113

7.  Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).

Authors:  Hiroya Tamaki; Machiko Mishima; Manabu Kawakami; Akihiro Tsuboi; Eui Ho Kim; Naoki Hosen; Kazuhiro Ikegame; Masaki Murakami; Tatsuya Fujioka; Tomoki Masuda; Yuki Taniguchi; Sumiyuki Nishida; Kazuoki Osumi; Toshihiro Soma; Yusuke Oji; Yoshihiro Oka; Ichiro Kawase; Haruo Sugiyama; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.

Authors:  Shao-An Xue; Liquan Gao; Sharyn Thomas; Daniel P Hart; John Zhao Xue; Roopinder Gillmore; Ralf-Holger Voss; Emma Morris; Hans J Stauss
Journal:  Haematologica       Date:  2009-08-13       Impact factor: 9.941

9.  EFFECT OF THAI SARAPHI FLOWER EXTRACTS ON WT1 AND BCR/ABL PROTEIN EXPRESSION IN LEUKEMIC CELL LINES.

Authors:  Rungkarn Sangkaruk; Methee Rungrojsakul; Singkome Tima; Songyot Anuchapreeda
Journal:  Afr J Tradit Complement Altern Med       Date:  2017-01-13

10.  Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.

Authors:  Alexander Spira; Aaron R Hansen; Wael A Harb; Kelly K Curtis; Erina Koga-Yamakawa; Makoto Origuchi; Zhonggai Li; Bella Ertik; Walid L Shaib
Journal:  Target Oncol       Date:  2021-05-03       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.